Quickstart Highlights

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) derived as an active metabolite of Melanotan II[1]. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women[2], bremelanotide enhances sexual desire by activating MC4R in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area[3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration using a practical dilution for clear insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.

• Typical daily range: 500–1500 mcg once daily (gradual titration over 16 weeks).

• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.

• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

 

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

 

 

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

WeekDaily Dose (mcg)Units (per injection) (mL)

Weeks 1–8/500 mcg (0.5 mg)/15 units (0.15 mL)

Weeks 9–12/1000 mcg (1.0 mg)/30 units (0.30 mL)

Weeks 13–16/1500 mcg (1.5 mg)/45 units (0.45 mL)

Route & Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery[3]. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month)[3]; however, daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction[4], suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.

2. Inject slowly down the vial wall; avoid foaming.

3. Gently swirl/roll until dissolved (do not shake).

4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

 

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (PT-141, 10 mg each):

   

  • 8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials

  • 12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials

  • 16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials

• Insulin Syringes (U-100):

   

  • Per week: 7 syringes (1/day)

  • 8 weeks: 56 syringes

  • 12 weeks: 84 syringes

  • 16 weeks: 112 syringes

• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

   

  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle

  • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles

  • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles

• Alcohol Swabs: One for the vial stopper + one for the injection site each day.

   

  • Per week: 14 swabs (2/day)

  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes

  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes

  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

​

 

 

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support sexual desire and arousal through central melanocortin receptor activation[3].

• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

• Dose Range: 500–1500 mcg daily with gradual titration.

• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.

• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 500 mcg daily for the first 8 weeks to assess tolerance.

• Escalate: Increase to 1000 mcg daily during Weeks 9–12.

• Target: 1500 mcg daily during Weeks 13–16 if well tolerated.

• Frequency: Once per day (subcutaneous).

• Timing: Any consistent time; rotate injection sites between abdomen and thighs.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[9].

• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.

 

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (27–30G, 5/8-inch needle) for each injection; dispose in a sharps container[7].

• Rotate injection sites (abdomen, thighs) on different days to avoid lipodystrophy or irritation[6].

• Inject slowly; wait a few seconds before withdrawing the needle.

• Nausea is the most common side effect and tends to be transient; flushing and headache may also occur[3].

• Document daily dose and site rotation to maintain consistency.

 

How This Works

Bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R[3]. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire[3]. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue[3]. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning)[3][5].

 

Potential Benefits & Side Effects

Observations from clinical trials and peer-reviewed literature.

• Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo[3].

• Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses and increasing arousal measures in women[1].

• Adverse effects are usually mild and transient: most commonly nausea (~40%), flushing, headache, and injection-site reactions[3][5].

• Transient increases in blood pressure have been reported; bremelanotide is not recommended for individuals with uncontrolled hypertension or cardiovascular disease[5][10].

• Skin darkening (hyperpigmentation) may occur with repeated use due to peripheral MC1R activation and is generally reversible[3].